PL346347A1 - Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof - Google Patents

Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Info

Publication number
PL346347A1
PL346347A1 PL99346347A PL34634799A PL346347A1 PL 346347 A1 PL346347 A1 PL 346347A1 PL 99346347 A PL99346347 A PL 99346347A PL 34634799 A PL34634799 A PL 34634799A PL 346347 A1 PL346347 A1 PL 346347A1
Authority
PL
Poland
Prior art keywords
processes
alendronate sodium
manufacture
pharmaceutical compositions
hydrate forms
Prior art date
Application number
PL99346347A
Other languages
English (en)
Inventor
Nina Finkelstein
Ramy Lidor-Hadas
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL346347A1 publication Critical patent/PL346347A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL99346347A 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof PL346347A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19

Publications (1)

Publication Number Publication Date
PL346347A1 true PL346347A1 (en) 2002-02-11

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99346347A PL346347A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Country Status (30)

Country Link
US (2) US6281381B1 (https=)
EP (1) EP1107974B1 (https=)
JP (2) JP2002523514A (https=)
KR (2) KR20070034132A (https=)
AT (1) ATE334993T1 (https=)
AU (1) AU5698899A (https=)
BG (1) BG65329B1 (https=)
BR (1) BR9913472A (https=)
CA (1) CA2341459A1 (https=)
CZ (1) CZ2001629A3 (https=)
DE (1) DE69932620T2 (https=)
DK (1) DK1107974T3 (https=)
EA (1) EA002739B1 (https=)
EE (1) EE04552B1 (https=)
ES (1) ES2270613T3 (https=)
HR (1) HRP20010129A2 (https=)
HU (1) HUP0203078A3 (https=)
IL (1) IL141423A (https=)
IS (1) IS5864A (https=)
LT (1) LT4888B (https=)
LV (1) LV12720B (https=)
NO (1) NO20010957L (https=)
NZ (1) NZ510682A (https=)
PL (1) PL346347A1 (https=)
PT (1) PT1107974E (https=)
RO (1) RO122854B1 (https=)
SI (1) SI20581B (https=)
SK (1) SK2482001A3 (https=)
WO (1) WO2000012517A1 (https=)
YU (1) YU14701A (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
DK2283825T3 (da) 2004-05-24 2022-06-27 Theramex Hq Uk Ltd Enterisk fast oral doseringsform af en bisfosfonat indeholdende et chelateringsmiddel
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
WO1996039149A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
CA2221844A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations

Also Published As

Publication number Publication date
LV12720B (en) 2002-02-20
EA200100184A1 (ru) 2001-10-22
US6281381B1 (en) 2001-08-28
RO122854B1 (ro) 2010-03-30
BR9913472A (pt) 2002-03-05
ATE334993T1 (de) 2006-08-15
SK2482001A3 (en) 2002-01-07
BG65329B1 (bg) 2008-02-29
NO20010957L (no) 2001-04-26
WO2000012517A1 (en) 2000-03-09
JP2009143955A (ja) 2009-07-02
LT2001016A (en) 2001-10-25
DK1107974T3 (da) 2006-10-30
EE04552B1 (et) 2005-10-17
NO20010957D0 (no) 2001-02-26
KR20070034132A (ko) 2007-03-27
BG105292A (en) 2001-12-29
KR20010079701A (ko) 2001-08-22
EP1107974A4 (en) 2001-09-26
HUP0203078A2 (hu) 2003-01-28
IL141423A0 (en) 2002-03-10
CA2341459A1 (en) 2000-03-09
DE69932620T2 (de) 2006-12-14
IS5864A (is) 2001-02-26
DE69932620D1 (de) 2006-09-14
LV12720A (lv) 2001-09-20
US6696601B2 (en) 2004-02-24
LT4888B (lt) 2002-02-25
WO2000012517A9 (en) 2000-07-13
AU5698899A (en) 2000-03-21
EP1107974A1 (en) 2001-06-20
HUP0203078A3 (en) 2005-01-28
IL141423A (en) 2005-09-25
NZ510682A (en) 2003-09-26
US20030065214A1 (en) 2003-04-03
HRP20010129A2 (en) 2005-04-30
SI20581B (sl) 2008-06-30
EA002739B1 (ru) 2002-08-29
PT1107974E (pt) 2006-10-31
YU14701A (sh) 2003-01-31
CZ2001629A3 (cs) 2001-08-15
ES2270613T3 (es) 2007-04-01
EE200100126A (et) 2002-06-17
SI20581A (sl) 2001-12-31
EP1107974B1 (en) 2006-08-02
JP2002523514A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
PL346347A1 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
DE60038038D1 (en) Phosphonatverbindungen
NZ272610A (en) The manufacture of dispersible tablets containing fluoxetine by direct compression
AU7642001A (en) Novel $G(Y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
ZA99913B (en) Alteration of amino acid compositions in seeds.
PL339548A1 (en) Implant for uniting two fragments of fractured bone
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
MY119970A (en) Method of fertilizing an avian egg in the shell
HU0102813D0 (en) New betha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it
HUP0401141A3 (en) Crystalline forms of fluvastatin sodium, process for their preparation and pharmaceutical compositions containing them
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
CA2431515A1 (en) Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
HUP9904564A3 (en) Substituted aminomethyl-cycloheptenes, process for producing them, their use, and pharmaceutical compositions containing them
HK1034715A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
WO2000076454A3 (en) Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions
ZA944317B (en) New phosphonosuccinic acid derivatives processes for the preparation thereof and pharmaceutical compositions containing them
MY118194A (en) Pharmaceutical compositions for use in inhibiting bone resorption
HUP9801781A3 (en) Process for producing indolil-methane compounds and pharmaceutical compositions for inhibiting transcriptase (rt) enzyme comprising the same compounds
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
HU0102815D0 (en) New alpha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)